[Form 4] Vaxcyte, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Harpreet S. Dhaliwal, Chief Technical Ops Officer at Vaxcyte, Inc. (PCVX), reported multiple common stock dispositions on 09/02/2025. The Form 4 shows three transactions coded F that disposed of 291, 783, and 464 shares respectively at $31.56 per share to satisfy tax withholding on RSU vesting. Following these transactions, the filing reports beneficial ownership levels of 36,121, 35,338, and 34,874 shares on the respective lines. The filing also notes that 329 shares acquired under the company’s Employee Stock Purchase Plan on May 16, 2025 are included in the reported beneficial ownership figure. The Form is signed by an attorney-in-fact on behalf of Mr. Dhaliwal.

Insights

Securities Analyst

TL;DR: Routine RSU tax-withholding share surrenders and an ESPP purchase; no new derivative or unusual trading activity disclosed.

The transactions are coded as F, consistent with share dispositions to cover tax withholding upon RSU vesting rather than open-market selling for liquidity. The per-share price reported is $31.56, and the filing separately notes an Employee Stock Purchase Plan allocation of 329 shares acquired May 16, 2025. For investors, this filing documents compliance with compensation tax obligations and shows a modest net reduction in directly held common shares by the reporting officer. There is no evidence in this Form 4 of option exercises, new grants, or derivative activity.

Corporate Governance Expert

TL;DR: Standard insider reporting; transactions appear administrative and consistent with equity compensation mechanics.

The filings indicate administrative dispositions (share surrender for tax withholding) rather than opportunistic sales or transfers. The inclusion of ESPP shares in the beneficial ownership tally is properly disclosed. The Form is signed by an attorney-in-fact, indicating standard execution practice. No governance red flags such as unexpected large disposals, stock pledges, or related-party transfers are disclosed in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dhaliwal Harpreet S.

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technical Ops Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		F		291(1)	D	$31.56	36,121(2)	D
Common Stock	09/02/2025		F		783(1)	D	$31.56	35,338	D
Common Stock	09/02/2025		F		464(1)	D	$31.56	34,874	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

2. Includes 329 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2025.

Remarks:

	Harpreet S. Dhaliwal, by /s/ Peter N. Efremenko, Attorney-In-Fact	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.